Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

Evolving Treatment Landscape of R/R HER2+ mBCПодробнее

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBCПодробнее

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancerПодробнее

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecanПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

The evolution of HER2-low breast cancer from primary to recurrenceПодробнее

Biological behaviour of HER2-low BC is dependent on HR expressionПодробнее

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBCПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer | Dr. Jitendra PahlajaniПодробнее

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast CancerПодробнее

The exciting new field of HER2-low breast cancerПодробнее

Evolving Treatment Landscape of R/R HER2+ mBCПодробнее

Evolving Treatment Landscape of R/R HER2+ mBCПодробнее

Clinical outcomes in women with metastatic HER2-low breast cancer in the real worldПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее